EDV nanocells coated with epidermal growth factor receptor (EGFR)-specific antibodies entered a phase I trial for the delivery of miR-16 mimics in patients with malignant pleural mesothelioma or non-small cell lung cancer (NSCLC). Here, EGFR is linked to malignant pleural mesothelioma.